US20080033290A1
Active / In Force
US
⏱️ 0.8 years remaining
Delivery of biological compounds to ischemic and/or infarcted tissue
Assignee: Voyage Medical Inc
•
Filing: 2007-07-25
•
Granted: —
•
Expires: 2027-07-25
Abstract
Abstract The delivery of biological compounds to ischemic and/or infarcted tissue are described herein where such a system may include a deployment catheter and an attached imaging hood deployable into an expanded configuration. In use, the imaging hood is placed against or adjacent to a region of tissue to be imaged in a body lumen that is normally filled with an opaque bodily fluid such as blood. A translucent or transparent fluid, such as saline, can be pumped into the imaging hood until the fluid displaces any blood, thereby leaving a clear region of tissue to be imaged via an imaging element in the deployment catheter. Additionally, any number of therapeutic tools can also be passed through the deployment catheter and into the imaging hood for performing any number of procedures on the tissue for identifying, locating, and/or accessing ischemic and/or infarcted tissue.
Inventors
- 👤 Vahid Saadat
- 👤 Sekhar Rao
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:44
CPC Classifications
A; A61; A61B; A61B1/00; A61B1/00147; A61B1/00148; A61B1/00064; A61B1/00071; A61B1/0008; A61B1/00089; A61B1/00096; A61B1/00163; A61B1/00165; A61B1/012; A61B1/015; A61B1/018; A61B1/04; A61B1/05; A61B1/12; A61B5/00; A61B5/0059; A61B5/0082; A61B5/0084; A61B5/68; A61B5/6846; A61B5/6879; A61B5/6882; A61B5/72; A61B5/7271; A61B5/7282; A61B1/005; A61B1/0051; A61B1/0057; A61M; A61M25/00; A61M25/0067; A61M25/0074; A61M25/0082; A61M25/0084
Claims Analysis
Total Claims: 53
Claim 1
Independent Claim
79 words
1 . A method of identifying a tissue region of interest for treatment, comprising: positioning an expanded barrier or membrane defining an open area and projecting distally from a deployment catheter against the tissue region of interest; urging a transparent fluid into the open area such that an opaque fluid is displaced therefrom; visualizing the tissue region of interest through the transparent fluid; and assessing at least one parameter of the tissue region for an indication of injured tissue.
Claim 2
Dependent Claim
79 words
1 . A method of identifying a tissue region of interest for treatment, comprising: positioning an expanded barrier or membrane defining an open area and projecting distally from a deployment catheter against the tissue region of interest; urging a transparent fluid into the open area such that an opaque fluid is displaced therefrom; visualizing the tissue region of interest through the transparent fluid; and assessing at least one parameter of the tissue region for an indication of injured tissue.
Claim 3
Dependent Claim
22 words
2 . The method of claim 1 wherein positioning comprises intravascularly advancing the deployment catheter into a chamber of a patient heart.
Claim 4
Dependent Claim
25 words
3 . The method of claim 1 wherein positioning comprises deploying the barrier or membrane from a low-profile delivery configuration into an expanded deployed configuration.
Claim 5
Dependent Claim
31 words
4 . The method of claim 1 wherein urging a transparent fluid comprises pumping the transparent fluid into the open area through a fluid delivery lumen defined through the deployment catheter.
Claim 6
Dependent Claim
29 words
5 . The method of claim 4 wherein pumping the transparent fluid comprises urging saline, plasma, water, or perfluorinated liquid into the open area such that blood is displaced.
Claim 7
Dependent Claim
24 words
6 . The method of claim 1 wherein visualizing comprises imaging the tissue region via an imaging element off-axis relative to the deployment catheter.
Claim 8
Dependent Claim
24 words
7 . The method of claim 1 wherein assessing comprises visually inspecting the tissue region for indications of ischemic and/or infarcted regions of tissue.
Claim 9
Dependent Claim
26 words
8 . The method of claim 7 further comprising administering a fluorescent compound upon or into the tissue region prior to visually inspecting the tissue region.
Claim 10
Dependent Claim
14 words
9 . The method of claim 8 wherein the fluorescent compound comprises indocyanin green.
Claim 11
Dependent Claim
24 words
10 . The method of claim 1 wherein assessing comprises measuring a partial pressure of oxygen and/or carbon dioxide present in the tissue region.
Claim 12
Dependent Claim
17 words
11 . The method of claim 1 wherein assessing comprises measuring a temperature of the tissue region.
Claim 13
Dependent Claim
21 words
12 . The method of claim 1 wherein assessing comprises measuring for a presence of a biomarker indicative of tissue injury.
Claim 14
Dependent Claim
35 words
13 . The method of claim 12 wherein the biomarker is selected from the group consisting of troponin T, troponin I, troponin C; creatine phosphokinase, MB fraction (CKMB), myoglobin, lactate dehydrogenase (LDH), and combinations thereof.
Claim 15
Dependent Claim
22 words
14 . The method of claim 1 wherein assessing comprises detecting differences in electrical current and/or electrical potential in the tissue region.
Claim 16
Dependent Claim
20 words
15 . The method of claim 1 wherein assessing comprises measuring relative tissue hardness and/or deflection over the tissue region.
Claim 17
Dependent Claim
23 words
16 . The method of claim 1 further comprising identifying the injured tissue based upon an assessment of the at least one parameter.
Claim 18
Dependent Claim
17 words
17 . The method of claim 16 further comprising treating the injured tissue with a bioactive agent.
Claim 19
Dependent Claim
22 words
18 . The method of claim 17 wherein treating comprises injecting or infusing the bioactive agent upon or into the injured tissue.
Claim 20
Dependent Claim
39 words
19 . The method of claim 17 wherein the bioactive agent is selected from the group consisting of stem cells, vascular endothelial growth factor, fibroblast growth factor, pro-angiogenic cytokines, tumor necrosis factor alpha, interleukin 8, SIKVAV, and neuropeptide Y.
Claim 21
Dependent Claim
17 words
20 . The method of claim 16 further comprising treating the injured tissue with a chemical irritant.
Claim 22
Dependent Claim
84 words
21 . A method of treating a tissue region of interest, comprising: positioning an expanded barrier or membrane defining an open area and projecting distally from a deployment catheter against the tissue region of interest; urging a transparent fluid into the open area such that an opaque fluid is displaced therefrom; visualizing the tissue region of interest through the transparent fluid; piercing at least partially into the tissue region with a delivery instrument; and delivering an agent through the instrument into the tissue region.
Claim 23
Dependent Claim
84 words
21 . A method of treating a tissue region of interest, comprising: positioning an expanded barrier or membrane defining an open area and projecting distally from a deployment catheter against the tissue region of interest; urging a transparent fluid into the open area such that an opaque fluid is displaced therefrom; visualizing the tissue region of interest through the transparent fluid; piercing at least partially into the tissue region with a delivery instrument; and delivering an agent through the instrument into the tissue region.
Claim 24
Dependent Claim
24 words
22 . The method of claim 21 further comprising assessing at least one parameter of the tissue region for an indication of injured tissue.
Claim 25
Dependent Claim
24 words
23 . The method of claim 22 wherein assessing comprises visually inspecting the tissue region for indications of ischemic and/or infarcted regions of tissue.
Claim 26
Dependent Claim
25 words
24 . The method of claim 21 wherein positioning comprises deploying the barrier or membrane from a low-profile delivery configuration into an expanded deployed configuration.
Claim 27
Dependent Claim
31 words
25 . The method of claim 21 wherein urging a transparent fluid comprises pumping the transparent fluid into the open area through a fluid delivery lumen defined through the deployment catheter.
Claim 28
Dependent Claim
29 words
26 . The method of claim 25 wherein pumping the transparent fluid comprises urging saline, plasma, water, or perfluorinated liquid into the open area such that blood is displaced.
Claim 29
Dependent Claim
24 words
27 . The method of claim 21 wherein visualizing comprises imaging the tissue region via an imaging element off-axis relative to the deployment catheter.
Claim 30
Dependent Claim
23 words
28 . The method of claim 21 wherein the delivery instrument comprises a needle defining a lumen through which the agent is delivered.
Claim 31
Dependent Claim
28 words
29 . The method of claim 21 wherein the delivery instrument comprises a helical needle having a plurality of openings therealong through which the agent may be delivered.
Claim 32
Dependent Claim
20 words
30 . The method of claim 21 wherein delivering an agent comprises administering a fluorescent compound into the tissue region.
Claim 33
Dependent Claim
20 words
31 . The method of claim 30 further comprising further visualizing the tissue region for an indication of injured tissue.
Claim 34
Dependent Claim
20 words
32 . The method of claim 21 wherein delivering an agent comprises administering a bioactive agent into the tissue region.
Claim 35
Dependent Claim
39 words
33 . The method of claim 32 wherein the bioactive agent is selected from the group consisting of stem cells, vascular endothelial growth factor, fibroblast growth factor, pro-angiogenic cytokines, tumor necrosis factor alpha, interleukin 8, SIKVAV, and neuropeptide Y.
Claim 36
Dependent Claim
16 words
34 . The method of claim 21 wherein delivering an agent comprises administering a chemical irritant.
Claim 37
Dependent Claim
17 words
35 . The method of claim 21 wherein delivering an agent comprises implanting an encapsulated bioactive substance.
Claim 38
Dependent Claim
91 words
36 . A system for identifying a tissue region of interest, comprising: a deployment catheter defining at least one lumen therethrough; a barrier or membrane projecting distally from the deployment catheter and defining an open area therein, wherein the open area is in fluid communication with the at least one lumen; a visualization element disposed within or along the barrier or membrane for visualizing tissue adjacent to the open area; and a sensor probe configured to assess at least one parameter of the tissue region for an indication of injured tissue.
Claim 39
Dependent Claim
91 words
36 . A system for identifying a tissue region of interest, comprising: a deployment catheter defining at least one lumen therethrough; a barrier or membrane projecting distally from the deployment catheter and defining an open area therein, wherein the open area is in fluid communication with the at least one lumen; a visualization element disposed within or along the barrier or membrane for visualizing tissue adjacent to the open area; and a sensor probe configured to assess at least one parameter of the tissue region for an indication of injured tissue.
Claim 40
Dependent Claim
16 words
37 . The system of claim 36 wherein the barrier is comprised of a compliant material.
Claim 41
Dependent Claim
27 words
38 . The system of claim 36 wherein the barrier or membrane is adapted to be reconfigured from a low-profile delivery configuration to an expanded deployed configuration.
Claim 42
Dependent Claim
15 words
39 . The system of claim 36 wherein the barrier or membrane is conically shaped.
Claim 43
Dependent Claim
22 words
40 . The system of claim 36 wherein the visualization element comprises at least one optical fiber, CCD imager, or CMOS imager.
Claim 44
Dependent Claim
29 words
41 . The system of claim 36 further comprising a fluorescent compound for injection or infusion upon or into the tissue region for facilitating imaging via the visualization element.
Claim 45
Dependent Claim
14 words
42 . The system of claim 41 wherein the fluorescent compound comprises indocyanin green.
Claim 46
Dependent Claim
28 words
43 . The system of claim 36 wherein the sensor probe is configured to measure a partial pressure of oxygen and/or carbon dioxide present in the tissue region.
Claim 47
Dependent Claim
21 words
44 . The system of claim 36 wherein the sensor probe is configured to measure a temperature of the tissue region.
Claim 48
Dependent Claim
25 words
45 . The system of claim 36 wherein the sensor probe is configured to measure for a presence of a biomarker indicative of tissue injury.
Claim 49
Dependent Claim
35 words
46 . The system of claim 45 wherein the biomarker is selected from the group consisting of troponin T, troponin I, troponin C; creatine phosphokinase, MB fraction (CKMB), myoglobin, lactate dehydrogenase (LDH), and combinations thereof.
Claim 50
Dependent Claim
26 words
47 . The system of claim 36 wherein the sensor probe is configured to detect differences in electrical current and/or electrical potential in the tissue region.
Claim 51
Dependent Claim
24 words
48 . The system of claim 36 wherein the sensor probe is configured to measure relative tissue hardness and/or deflection over the tissue region.
Claim 52
Dependent Claim
22 words
49 . The system of claim 36 further comprising a bioactive agent for injection or infusion upon or into the tissue region.
Claim 53
Dependent Claim
39 words
50 . The system of claim 49 wherein the bioactive agent is selected from the group consisting of stem cells, vascular endothelial growth factor, fibroblast growth factor, pro-angiogenic cytokines, tumor necrosis factor alpha, interleukin 8, SIKVAV, and neuropeptide Y.
References Cited (Backward Citations)
US3874388A
Cited
US4445892A
Cited
US4681093A
Cited
US4676258A
Cited
US4576146A
Cited
US4569335A
Cited
US4727418A
Cited
US4848323A
Cited
US5090959A
Cited
US5421338A
Cited
US5115626A
Cited
US4998916A
Cited
US4911148A
Cited
US4991578A
Cited
US5330496A
Cited
US5749846A
Cited
US5902328A
Cited
US6168594B1
Cited
US20040117032A1
Cited
US5713946A
Cited
US6751492B2
Cited
US5385148A
Cited
US5405376A
Cited
US5593405A
Cited
US5515853A
Cited
US5766137A
Cited
US5716321A
Cited
US5873815A
Cited
US5895417A
Cited
US6258083B1
Cited
US6174307B1
Cited
US6047218A
Cited
US5908445A
Cited
US5749890A
Cited
US20020026145A1
Cited
US6086534A
Cited
US6224553B1
Cited
US20050165391A1
Cited
US6682526B1
Cited
US20020087169A1
Cited
US20020087166A1
Cited
US6178346B1
Cited
US6396873B1
Cited
US6704043B2
Cited
US6840923B1
Cited
US6572609B1
Cited
US6673090B2
Cited
US6235044B1
Cited
US20010005789A1
Cited
US20050059954A1
Cited
US6755811B1
Cited
US7736347B2
Cited
US6385476B1
Cited
US20050165466A1
Cited
US20020004644A1
Cited
US20030130572A1
Cited
US6896690B1
Cited
US6858005B2
Cited
US6532380B1
Cited
US20020091304A1
Cited
US6587709B2
Cited
US20050107736A1
Cited
US7025746B2
Cited
US7019610B2
Cited
US20040097788A1
Cited
US20060025787A1
Cited
US20040054389A1
Cited
US6863668B2
Cited
US20040138707A1
Cited
US20050015048A1
Cited
US20050124969A1
Cited
US20050131401A1
Cited
US20050119523A1
Cited
US7534204B2
Cited
US20060149331A1
Cited
US20050159702A1
Cited
US20050154252A1
Cited
US7186214B2
Cited
US20060084945A1
Cited
US20060030844A1
Cited
US20060069303A1
Cited
US20060089637A1
Cited
US20090054803A1
Cited
US20080015445A1
Cited
US20080015569A1
Cited
US20110060298A1
Cited
US20110060227A1
Cited
US20080009747A1
Cited
US20070106287A1
Cited
US20070106146A1
Cited
US20070167801A1
Cited
US20080097476A1
Cited
US20080058590A1
Cited
US20090030412A1
Cited
US20090076498A1
Cited
US20090062790A1
Cited
US20090143640A1
Cited
US20110144576A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.